Italia markets closed

Bellerophon Therapeutics, Inc. (0HMP.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,0543-0,0047 (-7,97%)
Alla chiusura: 03:26PM BST
Schermo intero
Chiusura precedente0,0590
Aperto0,0543
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0543 - 0,0543
Intervallo di 52 settimane0,0315 - 12,3500
Volume2.297
Media Volume21.221
CapitalizzazioneN/D
Beta (5 anni mensile)0,68
Rapporto PE (ttm)N/D
EPS (ttm)-1,8850
Prossima data utili22 apr 2024 - 26 apr 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

    Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeu

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

    Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023. “We are pleased with the prog

  • GlobeNewswire

    Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

    Pivotal top-line data readout expected in mid-2023WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial l